CT-determined low skeletal muscle index predicts poor prognosis in patients with colorectal cancer

被引:3
|
作者
Feng, Yue [1 ,2 ]
Cheng, Xiao-Hong [3 ]
Xu, Mei [4 ]
Zhao, Rui [3 ]
Wan, Qian-Yi [3 ]
Feng, Wei-Hua [5 ]
Gan, Hua-Tian [1 ,2 ,6 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Geriatr, 37 Guo Xue Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, 37 Guo Xue Rd, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Gen Surg, Div Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Sichuan, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu 610041, Sichuan, Peoples R China
[6] Sichuan Univ, West China Hosp, Clin Inst Inflammat & Immunol, Frontiers Sci Ctr Dis Related Mol Network,Ctr Infl, Chengdu, Peoples R China
来源
CANCER MEDICINE | 2024年 / 13卷 / 12期
基金
中国国家自然科学基金;
关键词
colorectal cancer; major complications; overall survival; sarcopenia; CLINICAL-IMPLICATIONS; SARCOPENIC OBESITY; SOLID TUMORS; CHEMOTHERAPY; ASSOCIATION; DIAGNOSIS; SURVIVAL; CACHEXIA; OUTCOMES; MASS;
D O I
10.1002/cam4.7328
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Sarcopenia is highly prevalent among patients with colorectal cancer (CRC). Computed tomography (CT)-based assessment of low skeletal muscle index (SMI) is widely used for diagnosing sarcopenia. However, there are conflicting findings on the association between low SMI and overall survival (OS) in CRC patients. The objective of this study was to investigate whether CT-determined low SMI can serve as a valuable prognostic factor in CRC. Methods We collected data from patients with CRC who underwent radical surgery at our institution between June 2020 and November 2021. The SMI at the third lumbar vertebra was calculated using CT scans, and the cutoff values for defining low SMI were determined using receiver operating characteristic curves. Univariate and multivariate analyses were performed to assess the associations between clinical characteristics and postoperative major complications. Results A total of 464 patients were included in the study, 229 patients (46.7%) were classified as having low SMI. Patients with low SMI were older and had a lower body mass index (BMI), a higher neutrophil to lymphocyte ratio (NLR), and higher nutritional risk screening 2002 (NRS2002) scores compared to those with normal SMI. Furthermore, patients with sarcopenia had a higher rate of major complications (10.9% vs. 1.3%; p < 0.001) and longer length of stay (9.09 +/- 4.86 days vs. 8.25 +/- 3.12 days; p = 0.03). Low SMI and coronary heart disease were identified as independent risk factors for postoperative major complications. Moreover, CRC patients with low SMI had significantly worse OS. Furthermore, the combination of low SMI with older age or TNM stage II + III resulted in the worst OS in each subgroup analysis. Conclusions CT-determined low SMI is associated with poor prognosis in patients with CRC, especially when combined with older age or advanced TNM stage.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia
    Wan, Qianyi
    Wang, Zhetao
    Zhao, Rui
    Tu, Tingting
    Shen, Xiaoding
    Shen, Yuhou
    Li, Tao
    Chen, Yi
    Song, Yinghan
    CANCER MEDICINE, 2023, 12 (02): : 1492 - 1500
  • [2] Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy
    Aichi, Masahiro
    Hasegawa, Sho
    Kurita, Yusuke
    Shinoda, Satoru
    Kato, Shingo
    Mizushima, Taichi
    Yokota, Naho Ruiz
    Miyagi, Etsuko
    NUTRITION, 2023, 109
  • [3] Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
    Amitani, Masatsugu
    Oba, Takaaki
    Kiyosawa, Nami
    Morikawa, Hiroki
    Chino, Tatsunori
    Soma, Ai
    Shimizu, Tadafumi
    Ohno, Koichi
    Ono, Mayu
    Ito, Tokiko
    Kanai, Toshiharu
    Maeno, Kazuma
    Ito, Ken-ichi
    BMC CANCER, 2022, 22 (01)
  • [4] Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
    Masatsugu Amitani
    Takaaki Oba
    Nami Kiyosawa
    Hiroki Morikawa
    Tatsunori Chino
    Ai Soma
    Tadafumi Shimizu
    Koichi Ohno
    Mayu Ono
    Tokiko Ito
    Toshiharu Kanai
    Kazuma Maeno
    Ken-ichi Ito
    BMC Cancer, 22
  • [5] Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer
    Cai, Jun
    Ma, Hong
    Huang, Fang
    Zhu, Dichao
    Zhao, Lei
    Yang, Yudan
    Bi, Jianping
    Zhang, Tao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (08): : 4959 - 4970
  • [6] MMP14 predicts a poor prognosis in patients with colorectal cancer
    Cui, Guangfei
    Cai, Feng
    Ding, Zhanwei
    Gao, Ling
    HUMAN PATHOLOGY, 2019, 83 : 36 - 42
  • [7] Underweight status predicts a poor prognosis in elderly patients with colorectal cancer
    Kaneko, Manabu
    Sasaki, Shin
    Ozaki, Kosuke
    Ishimaru, Kazuhiro
    Terai, Emi
    Nakayama, Hiroshi
    Watanabe, Toshiyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (03) : 289 - 294
  • [8] High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer
    Wang, Xiaopeng
    Lin, Ruirong
    Zeng, Yi
    Wang, Yi
    Wei, Shenghong
    Lin, Zhitao
    Chen, Shu
    Ye, Zaisheng
    Chen, Luchuan
    FRONTIERS IN GENETICS, 2022, 13
  • [9] Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer
    Kostek, O.
    Demircan, N. C.
    Gokyer, A.
    Kucukarda, A.
    Sunal, B. S.
    Hacioglu, M. B.
    Eslame, H.
    Solak, S.
    Yilmaz, E.
    Uzunoglu, S.
    Tuncbilek, N.
    Cicin, I.
    Erdogan, B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11): : 1510 - 1517
  • [10] Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer
    O. Köstek
    N. C. Demircan
    A. Gökyer
    A. Küçükarda
    B. S. Sunal
    M. B. Hacıoğlu
    H. Eslame
    S. Solak
    E. Yılmaz
    S. Uzunoğlu
    N. Tunçbilek
    İ. Çiçin
    B. Erdoğan
    Clinical and Translational Oncology, 2019, 21 : 1510 - 1517